

<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>		ATTORNEY DOCKET NO. P0889US00/BAS
INTERNATIONAL APPLICATION NO. PCT/IB04/03146	INTERNATIONAL FILING DATE 28 September 2004	US APPL. NO. (If known, see 37CFR 1.5) 10/573,804
TITLE OF INVENTION: IDENTIFICATION OF POLYMORPHISMS IN THE EPCR GENE ASSOCIATED WITH...		
APPLICANT(S) FOR DO/EO/US: AIACH		
<p>Applicant herewith submits to the US Designated/Elected Office (DO/EO/US) the following items and other information:</p> <p><input type="checkbox"/> 1. This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p><input checked="" type="checkbox"/> 2. This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 USC 371.</p> <p><input type="checkbox"/> 3. This is an express request to begin national examination procedures (35 USC 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p><input type="checkbox"/> 4. The US has been elected (Article 31).</p> <p><input type="checkbox"/> 5. A copy of the International Application as filed (35 U.S.C. 371 (c)(2))</p> <p><input type="checkbox"/> a. is attached hereto (required only if not communicated by the International Bureau).</p> <p><input type="checkbox"/> b. has been communicated by the International Bureau</p> <p><input type="checkbox"/> c. is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p><input type="checkbox"/> 6. An English translation of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <p><input type="checkbox"/> a. is attached hereto.</p> <p><input type="checkbox"/> b. has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p><input type="checkbox"/> c. is not needed since the International Application is in English.</p> <p><input type="checkbox"/> 7. Amendments to the claims of the International Appln. under PCT Article 19 (35 USC 371 (c)(3))</p> <p><input type="checkbox"/> a. are attached hereto (required only if not communicated by the International Bureau).</p> <p><input type="checkbox"/> b. have been communicated by the International Bureau.</p> <p><input type="checkbox"/> c. have not been made; however, the time limit for making such amendments has NOT expired.</p> <p><input type="checkbox"/> d. have not been made and will not be made.</p> <p><input type="checkbox"/> 8. An English translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p><input checked="" type="checkbox"/> 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p><input type="checkbox"/> 10. An English translation of the annexes to the Int'l Pre. Exam. Report under PCT Article 36 (35 USC 371(c)(5)).</p>		
<p>Items 11. to 20. below concern document(s) or information included:</p> <p><input checked="" type="checkbox"/> 11. An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.</p> <p><input type="checkbox"/> 12. An Assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 &amp; 3.31 is included.</p> <p><input checked="" type="checkbox"/> 13. A preliminary amendment.</p> <p><input type="checkbox"/> 14. An Application Data Sheet under 37 CFR 1.76.</p> <p><input type="checkbox"/> 15. A substitute specification.</p> <p><input type="checkbox"/> 16. A power of attorney and/or change of address letter.</p> <p><input type="checkbox"/> 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 &amp; 37 CFR 1.821-825.</p> <p><input type="checkbox"/> 18. A second copy of the published international application under 35 USC 154(d)(4).</p> <p><input type="checkbox"/> 19. A second copy of the English translation of the international application under 35 USC 154(d)(4).</p> <p>20. Other items or information:</p> <p><input type="checkbox"/> Return Receipt Postcard.</p> <p><input checked="" type="checkbox"/> A copy of the Notification of Missing Requirements under 35 U.S.C. 371.</p> <p><input checked="" type="checkbox"/> In the event that a petition for extension of time is required to be submitted herewith, and in the event that a separate petition does not accompany this response, applicant hereby petitions under 37 CFR 1.136(a) for an extension of time of as many months as are required to render this submission timely. Any fee is authorized in 21(c).</p> <p><input type="checkbox"/></p>		

U.S. APPLICATION NO. (if known) 10/573,804	INTERNATIONAL APPLICATION NO. PCT/IB04/03146	ATTORNEY DOCKET NO. P08898US00/BAS	
The following fees have been submitted:		CALCULATIONS	
<input type="checkbox"/> 21. Basic national fee (37 CFR 1.492(a)) <input type="checkbox"/> 22. Examination fee (37 CFR 1.492(c)) <input type="checkbox"/> Written Opinion or IPER by US indicates all claims satisfy PCT Art. 33(1-4) \$0 <input type="checkbox"/> All other situations \$200		\$	
<input type="checkbox"/> 23. Search fee <input type="checkbox"/> Written Opinion or IPER by US indicates all claims satisfy PCT Art. 33(1-4) \$0 <input type="checkbox"/> Has been paid on the Int'l Appln. to the USPTO as ISA \$100 <input type="checkbox"/> International Search Report prepared and provided to the Office \$400 <input type="checkbox"/> All other situations \$500		\$ <i>fc COPY</i>	
TOTAL OF 21, 22 AND 23 \$			
<input type="checkbox"/> SIZE FEE: sheets - 100 = + 50 = [rounded up] x \$250 =		\$	
<input type="checkbox"/> Surcharge of \$130 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)) \$130		\$130	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total Claims	11 - 20 =	0	X \$50 = \$0
Independent Claims	3 - 03 =	0	X \$200 = \$0
<input type="checkbox"/> Multiple Dependent Claim(s) (if applicable) + \$360 =		\$	
TOTAL OF ABOVE CALCULATIONS = \$130			
<input type="checkbox"/> Applicant claims small entity status - 37 CFR 1.27. Fees above reduced by 1/2.		\$	
SUBTOTAL = \$130			
<input checked="" type="checkbox"/> Fee for Extension of Time \$120		\$	
TOTAL NATIONAL FEE = \$			
<input type="checkbox"/> Fee for recording enclosed assignment (37 CFR 1.21(h)). Assignment must be accompanied by appropriate cover sheet (37 CFR 3.28, 3.31) \$40 per property		\$	
TOTAL FEES ENCLOSED = \$250			
15/23/2007 MKAYPAGH 00000020 10573804 11 FC:1617	Amount to be	Refunded \$ Charged \$	
130.00 0P			
<input checked="" type="checkbox"/> Payment of \$250 is made by attached Credit Card Payment Form (PTO-2038) <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required for this submission (except claims fees if the box below is checked) or credit any overpayment to Deposit Account No. 12-0555. <input type="checkbox"/> Do not charge any claim fees now - any additional claims fees will be paid with the Missing Requirements.			
<b>NOTE:</b> Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.			
POWER OF ATTORNEY & CORRESPONDENCE ADDRESS:  CUSTOMER NO. 00881  Date: May 21, 2007	NAME: B. Aaron Schulman REG. NO.: 31,877  Signed (for) by:  REG. NO.: 31,877		

<b>PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a)</b>	Application #	10/573,804
	Confirmation #	9377
	Filing Date	March 28, 2006
	First Inventor	AIACH
	Art Unit	
	Examiner	
	Docket #	P08898US00/BAS

This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified application.

The requested extension and fee under 37 CFR 1.17(a) are as follows.

NOTE: Applicant claims small entity status.

**OCOPY**

No extension of time previously obtained.

<u>Time Period</u>	<u>Large Entity Fee</u>	<u>Small Entity Fee</u>
<input checked="" type="checkbox"/> One month	<input checked="" type="checkbox"/> \$ 120	<input type="checkbox"/> \$ 60
<input type="checkbox"/> Two months	<input type="checkbox"/> \$ 450	<input type="checkbox"/> \$ 225
<input type="checkbox"/> Three months	<input type="checkbox"/> \$ 1020	<input type="checkbox"/> \$ 510
<input type="checkbox"/> Four months	<input type="checkbox"/> \$ 1590	<input type="checkbox"/> \$ 795
<input type="checkbox"/> Five months	<input type="checkbox"/> \$ 2160	<input type="checkbox"/> \$ 1080

Payment by credit card. FORM PTO-2038 in the amount of \$250 is attached.

The Director is authorized to charge any fee or additional fee due in connection herewith to Deposit Account No. 12-0555:


- (1) if no payment or an insufficient payment is enclosed and a fee is due in connection herewith; or
- (2) if a further fee and petition for extension of time are required at this time - and in this event, applicant hereby petitions under 37 CFR 1.136(a) for any further extension of time of as many months as are required to render this submission timely.

Date: May 21, 2007

15/23/2007 MCKAYPAGH 00000020 10573804

02 FC:1251

Signed By  
120.00  
Attorney of Record

  
Name: B. Aaron Schulman  
Registration No.: 31,877

STITES & HARBISON PLLC • 1199 North Fairfax St. • Suite 900 • Alexandria, VA 22314  
TEL: 703-739-4900 • FAX: 703-739-9577 • CUSTOMER NO. 00881

<b>PRELIMINARY AMENDMENT</b>	Application #	10/573,804
	Confirmation #	9377
	Filing Date	03/28/06
	First Inventor	AIACH
	Art Unit	
	Examiner	
	Docket #	P08898US00/BAS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**COPY**

SIR:

Prior to examination

A) please consider the responsive **Remarks and Statement** provided herewith in

**Attachment A**; and


B) please amend the above identified application as follows:

- After page 29, please insert the **attached sequence listing** and substitute this listing for the one originally filed.
- A **Computer Readable Form** of the sequence listing is also provided.
- **Amendments to the Claims** are reflected in the listing of the claims provided herewith in **Attachment B**.

In view of the amendments made and the remarks provided, it is submitted that the present application is now in condition for examination and allowance.

Respectfully submitted,

Date: May 21, 2007

  
By: B. Aaron Schulman  
Registration No.: 31,877

**STITES & HARBISON PLC** • 1199 North Fairfax St. • Suite 900 • Alexandria, VA 22314  
TEL: 703-739-4900 • FAX: 703-739-9577 • CUSTOMER No. 000881

**ATTACHMENT A**

**REMARKS**

By the present amendment, a sequence listing and diskette in suitable US form are now provided. Applicants state as follows:

**STATEMENT**

Applicants state in accordance with 37 C.F.R. § 1.821(f) that the content of the enclosed paper sequence listing and computer readable form are the same, and that in accordance with 37 C.F.R. § 1.821(g), the enclosed submission contains no new matter.

Applicants submit that this application is now in compliance with sequence listing requirements. The claims have also been amended to eliminate multiple dependencies.

Accordingly, Applicants submit that the present application is now in condition for examination and allowance.

**END OF REMARKS**

 COPY

**ATTACHMENT B**  
**Amendments to the Claims**

**COPY**

*This listing of claims will replace all prior versions, and listings, of claims in the application.*

1. (Original) An *in vitro* method for determining the risk of developing thrombosis in a subject, which method comprises identifying polymorphisms of EPCR gene on at least one of positions 1651, 3610, 4216, and 6936 (SEQ 10 NO:1), wherein the presence of G at position 1651, C at position 3610, A at position 4216, or G at position 6936 is indicative of a higher risk to develop thrombosis in comparison with a control subject that does not show the same polymorphisms.

2. (Original) An *in vitro* method according to claim 1, which method comprises identifying polymorphisms of EPCR gene at positions 1651, 3610, 4216, 6936, 3787, 3877, 4868, 5233, 5760, 6333, 7014, 7968, 7999 of SEQ 10 NO: 1, wherein the simultaneous presence of :

- G at position 1651
- C at position 3610
- A at position 4216
- G at position 6936
- C at position 3787
- G at position 3877
- T at position 4868
- G at position 5233
- T at position 5760

- T at position 6333
- G at position 7014
- A at position 7968
- G at position 7999

 COPY

are designated A3 haplotype and, when present on at least one allele, are indicative of a higher risk to develop thrombosis in comparison with a control subject without any A3 allele.

3. (Currently Amended) The method according to claim 1-or-2, wherein said thrombosis is a venous thrombosis.

4. (Currently Amended) The method according to any-of-claims 1-to-3, wherein the analysis is undertaken on genomic DNA that is extracted from a biological sample of the subject.

5. (Currently Amended) The method according to any-of-claims 1-to-4, wherein the analysis comprises a step of amplification of the genomic DNA.

6. (Currently Amended) The method according to any-of-claims 1-to-5, wherein the polymorphisms of the EPCR gene are identified by sequencing.

7. (Currently Amended) The method according to any-of-claims 1-to-6, wherein at least one of the polymorphisms of the EPCR gene is identified by RFLP analysis.

8. (Original) The method according to claim 7, comprising identifying the polymorphism of EPCR gene on position 6936, by creating a restriction site for endonuclease PstI by amplification of the EPCR gene with mutagenic primers, when the amplified fragment contains an A at position 6936, so that when the amplified fragment containing a G, it remains undigested.

9. (Original) An isolated nucleic acid encoding the EPCR receptor, that comprises SEQ ID NO:2.

10. (Currently Amended) A kit suitable for the methods according to any of claims 1 to 6, which kit comprises a pair of nucleotide primers specific for amplifying all or part of the EPCR gene comprising at least one of positions 1651,3610,4216 of SEQ ID NO:1.

11. (Original) A method for genotyping the EPCR gene, which method comprises identifying the polymorphism of the EPCR gene at position 4216 (SEQ ID NO: 1), wherein the presence of C at position 4216 shows the A1 haplotype, the presence of G at position 4216 shows the A2 haplotype, and the presence of A shows the A3 haplotype.

**SEQUENCE LISTING**

<110> AIACH et al.

<120> Identification of polymorphisms in the EPCR gene associated with thrombotic risk

<130> P08899US00/BAS

<140> 10/573,804

<141> 2006-03-28

<160> 18

<170> PatentIn Ver. 2.1

<210> 1

<211> 8167

<212> DNA

<213> *Homo sapiens*

<400> 1

 COP

<210> 2

<211> 8167

<212> DNA

<213> *Homo sapiens*

<400> 2



gggtaaaaaa ggaggcaga aggagtgct cttecaactgc aggectcaat ttcteateat 4680  
 gttaaacgga gataataatc ctgtctgt cctctgca gagttactgt cagcgtcaaa 4740  
 cgggagaagg ggtggggagg cacattatag ttatcgaaagg gtcgagaagg cggccggcca 4800  
 gcctcgaggt aggggttat tatcttcgc tgcccgccg ccctcccaac gccggcccg 4860  
 gctgaatgtt actctccgcg caggccctca aagacttcat atgctccaga tctctactt 4920  
 ccgcacccgg tatacgctgt ggttccaggc caacgcgtcg ctggggggac acctaaca 4980  
 cgtgtggaa ggcggacaca ccaacaccac gatcattcag ctgcagccct tgcaaggcgc 5040  
 cgagagctgg ggcgcacgc agagtggct gcaacttac ctgtcccaat tccacggcc 5100  
 cgtgtccggc gtgcacccagg agccggacccgt ggccctgtgg taggcgcgcga gggggggccg 5160  
 ggcttggggc ggctctgtt gggccggggc tggccgggtt gggccggggc tggccgtatgg 5220  
 aggcggctgtt ggctctgtgg gggccggggc gcaacttgcgg ctccgggtggc cttggccctt 5280  
 tgaaggatgtc tggggggggg ctggagagac gcaacttgcgg ctgcgtttttt 5340  
 cggccggctgtt ctgttgcgc aataaccctt gggatagacca ctgtttttttt 5400  
 cgtgtccggc aagggtccca ccaaccccttcc cttccatccgc tccacacttcc 5460  
 ttcttcata gatccctgcg tttcccttcac cacagcccccc agcaacttcc ccccccaccc 5520  
 ccagccactt ctcatataag ctgtatgtt cgtcttttgc tccactatcg accccgaactc 5580  
 ttcccccacaa gggcccaatgt ttttttttttca aaggcccaactt cttcccccgtt cacaaccctt 5640  
 atcttcattttt ctcaaaagacca ccaatttttt ttttttttttca aaggcccaactt cttcccccgtt 5700  
 cttcccccacca ccatcatggc cttaatttc ttttttttttca aggcccaactt cttcccccgtt 5760  
 tttttttttttt ttttttttttca aggcccaactt cttcccccgtt cttcccccgtt 5820  
 gtgcgttgcg ggcgttccggc ttttttttttca aaggcccaactt cttcccccgtt 5880  
 tgccttcacccggc tcccaaaaggc ctggggactac aggcacccggc caccacggccc ggcttaatttt 5940  
 ttgtatgtt agtagagacca gggccggggc ttttttttttca aaggcccaactt cttcccccgtt 6000  
 cttccggggc tcccaaaaggc tggcccttca aaggccgtggg attacaggccg ttttttttttca 6060  
 cccctggccggc agccgttccccccttccggc ttttttttttca aaggccgtggc aaccgttcccccgtt 6120  
 attcattttttt ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc aaccgttcccccgtt 6180  
 caaaccccttc ctcacagccca caggcccttc tccctatgt tccctgtactt agactccccc 6240  
 ctcccttcacccggc ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 6300  
 acacccgttgcac cccttcttcgca agactcccccgttgcacttgcacttgc ttttttttttca 6360  
 accatccgcgtt gtttttttttca aaggccgtggc ttttttttttca aaggccgtggc 6420  
 ttccaaatgtt ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 6480  
 caggccggc ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 6540  
 ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 6600  
 cagaacacata ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 6660  
 gctggggggc gggccgggttc cagacaaatgtt gatggacttgg aaggatggat gcttagagca 6720  
 acaaaaggccg cacaatgtt gtttttttttca aaggccgtggc ttttttttttca aaggccgtggc 6780  
 acggggccctt ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 6840  
 tggggggccca ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 6900  
 octacttccatgtt ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 6960  
 taggttccatgtt ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 7020  
 gggccgtggat ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 7080  
 ccaacttgcacccggc ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 7140  
 tgaaggatgtt ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 7200  
 aaccaatgtt ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 7260  
 gtggggggccca ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 7320  
 acaacccatgtt ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 7380  
 acaacccatgtt ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 7440  
 gaaagaatgtt ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 7500  
 attatgttccatgtt ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 7560  
 cactttccatgtt ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 7620  
 actctttccatgtt ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 7680  
 ctggggccca ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 7740  
 ctcccttcacccggc ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 7800  
 ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 7860  
 gcttccatgtt ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 7920  
 actctttccatgtt ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 7980  
 acctttccatgtt ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 8040  
 ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 8100  
 ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc ttttttttttca aaggccgtggc 8160  
 agaattc

ECOPY

<210> 3  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence:PCR primer  
  
<400> 3  
gctgaagtgg gcggatcacc 20  
  
<210> 4  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence:PCR primer  
  
<400> 4  
tcttagctgg gtcatgcggc 20  
  
<210> 5  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence:PCR primer  
  
<400> 5  
tcttgccgca tgacccaggc 20  
  
<210> 6  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence:PCR primer  
  
<400> 6  
ggaaggaggc caggagatgg 20  
  
<210> 7  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence:PCR primer  
  
<400> 7  
ctcttactaa gggtgacgcg 20

<210> 8  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:PCR primer

<400> 8  
tctgatgccc cacgagacac 20

<210> 9  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:PCR primer

<400> 9  
tctctacagg gcaggcagag 20

<210> 10  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:PCR primer

<400> 10  
tcgtggtgtt ggtgtctggg 20

<210> 11  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:PCR primer

<400> 11  
aggagtgct cttccactgc 20

<210> 12  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:PCR primer

<400> 12  
cttgtatgag aagtggctgg 20

<210> 13

<211> 21  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> Description of Artificial Sequence:PCR primer

<400> 13  
cccgagacacc aacaccacga t 21

<210> 14  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> Description of Artificial Sequence:PCR primer

<400> 14  
gtctgtcttt ggaggatggg 20

<210> 15  
<211> 21  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> Description of Artificial Sequence:PCR primer

<400> 15  
agaggtggac aaagtacttg g 21

<210> 16  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> Description of Artificial Sequence:PCR primer

<400> 16  
ggaagccagc atttccaggg 20

<210> 17  
<211> 35  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> Description of Artificial Sequence:PCR primer

<400> 17  
cctacacttc gctggtcctg ggcgtcctgg tctgc 35

<210> 18  
<211> 22

~~DCOPY~~

<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:PCR primer

<400> 18  
caagtacttt gtccacacctct cc

22



## UNITED STATES PATENT AND TRADEMARK OFFICE

COPY

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 Washington, DC 20591-0000  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/573,804	Martine Aiach	P08898US00BAS
		INTERNATIONAL APPLICATION NO.
		PCT/IB04/03146
881		LA. FILING DATE
STITES & HARBISON PLLC 1199 NORTH FAIRFAX STREET SUITE 900 ALEXANDRIA, VA 22314		09/28/2004
RECEIVED		PRIORITY DATE
		09/29/2003
FEB 22 2007		CONFIRMATION NO. 9377
STITES & HARBISON PLLC		371 FORMALITIES LETTER
		*OC000000022559297*

Date Mailed: 02/21/2007

4-21-2007

**NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)**

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 03/28/2006
- Copy of the International Search Report filed on 03/28/2006
- U.S. Basic National Fees filed on 03/28/2006
- Priority Documents filed on 03/28/2006

COPY

The applicant needs to satisfy supplemental fees problems indicated below.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Additional claim fees of **\$360** as a non-small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.
- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and International filing date.
- To avoid abandonment, a surcharge (for late submission of filing fee, search fee, examination fee or oath or declaration) as set forth in 37 CFR 1.492(h) of **\$130** for a non-small entity, must be submitted with the missing items identified in this letter.

## SUMMARY OF FEES DUE:

Total additional fees required for this application is **\$490** for a Large Entity:

- **\$130** Surcharge.

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

- Total additional claim fee(s) for this application is \$ 360

- \$360 for multiple dependent claim surcharge.

**COPY**

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

**ECOPY**

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.  
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

ANITA D JOHNSON

Telephone: (703) 308-9140 EXT 226

## PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/573,804	PCT/IB04/03146	P08898US00BAS

FORM PCT/DO/EO/905 (371 Formalities Notice)

ccOPY

COPY

**DECLARATION FOR UTILITY OR  
DESIGN PATENT APPLICATION  
(37 CFR 1.63)**

Docket No.

1<sup>st</sup> Inventor

COMPLETE IF KNOWN

Appl. No.

Filing Date

Declaration Submitted with Initial Filing  
Declaration Submitted after Initial Filing

I hereby declare that:

Each inventor's residence, mailing address and citizenship are as stated below next to their name.

I believe the inventor(s) named below to be the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**Identification of polymorphisms in the EPCR gene associated with thrombotic risk.**

the specification of which:

is attached hereto

**OR**was filed on September 28, 2004 as PCT International Application No. PCT/IB2004/003146  
and (if applicable) was amended on .

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim PRIORITY benefits under 35 USC 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's certificate(s), or 365(a) of any PCT International application which designated at least one country other than the US, listed below and have also identified below, by checking the box, any foreign application for patent, Inventor's certificate(s), or any PCT International application having a filing date before that of the application on which priority is claimed. Additional applications listed on supplemental sheet provided herewith

Prior Foreign Appl. No.	Country	Filing Date (Day/Month/Year)	Priority Not Claimed
03292392.2	EUROPE	29.09.2003	Yes

**Power Of Attorney & Correspondence Address Indication**

CUSTOMER NUMBER 00881

I hereby appoint the practitioners (of Stites &amp; Harbison PLLC) associated with as my/lour attorneys or agents to prosecute the application identified above, and to transact all business in the US Patent and Trademark Office connected therewith.

Please direct all correspondence to the noted Customer Number.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 USC 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. Additional inventors named on supplemental sheet provided herewith
**SOLE OR FIRST INVENTOR**

Citizenship

French

Family Name or Surname

AIACH

Given Name (First and Middle if any)

Martine

Full Mailing Address

70 rue Brancas – 92310 SEVRES - FRANCE

Residence - City, State/Country

"same as above"

SIGN AND

DATE HERE

Inventor's Signature

Date

April 3, 2006

**SECOND JOINT INVENTOR (if any)**

Citizenship

French

Family Name or Surname

GANDRILLE

Given Name (First and Middle if any)

Sophie

Full Mailing

Address

197 rue de Lourmel – 75015 PARIS - FRANCE

Residence - City, State/Country

"same as above"

SIGN AND

DATE HERE

Inventor's Signature

Date

April 3, 2006

**THIRD JOINT INVENTOR (if any)**

Citizenship

French

Family Name or Surname

SAPOSNIK

Given Name (First and Middle if any)

Béatrice

Full Mailing

Address

85 avenue du Général Michel Bizot – 75012 PARIS - FRANCE

Residence - City, State/Country

"same as above"

SIGN AND

DATE HERE

Inventor's Signature

Date

April 5, 2006

**DCOPY**

Customized PTO/SB/01 (08-03)

**DECLARATION FOR UTILITY OR  
DESIGN PATENT APPLICATION  
(37 CFR 1.63)**
**SUPPLEMENTAL SHEET**

(use as required)

Docket No.

1<sup>st</sup> Inventor

COMPLETE IF KNOWN

Serial No.

Filing Date

Additional Prior Foreign Application(s):

Prior Foreign Appl. No.	Country	Day/Month/Year Filed	Priority Not Claimed

## Name Of Additional Joint Inventor, if any

Citizenship

French

Given Name (First and Middle (if any)) Pascale  
Full Mailing Address 8 rue du Général Castelnau – 94240 L'HAY LES ROSES - FRANCE

Family Name or Surname

GAUSSEM

Residence - City, State/Country (if different from mailing address) "Same as above"

SIGN AND DATE HERE Inventor's Signature

Date APRIL 5th, 2006

## Name Of Additional Joint Inventor, if any

Citizenship

French

Given Name (First and Middle (if any)) Joseph  
Full Mailing Address 112 rue Rambuteau – 75001 PARIS - FRANCE

Family Name or Surname

EMMERICH

Residence - City, State/Country (if different from mailing address) "Same as above"

SIGN AND DATE HERE Inventor's Signature

Date April 3, 2006

## Name Of Additional Joint Inventor, if any

Citizenship

Given Name (First and Middle (if any))  
Full Mailing Address  
Residence - City, State/Country (if different from mailing address)

Family Name or Surname

SIGN AND DATE HERE Inventor's Signature

Date

## Name Of Additional Joint Inventor, if any

Citizenship

Given Name (First and Middle (if any))  
Full Mailing Address  
Residence - City, State/Country (if different from mailing address)

Family Name or Surname

SIGN AND DATE HERE Inventor's Signature

Date

## Name Of Additional Joint Inventor, if any

Citizenship

Given Name (First and Middle (if any))  
Full Mailing Address  
Residence - City, State/Country (if different from mailing address)

Family Name or Surname

SIGN AND DATE HERE Inventor's Signature

Date

## Name Of Additional Joint Inventor, if any

Citizenship

Given Name (First and Middle (if any))  
Full Mailing Address  
Residence - City, State/Country (if different from mailing address)

Family Name or Surname

SIGN AND DATE HERE Inventor's Signature

Date

fc COPY

<b>INFORMATION DISCLOSURE STATEMENT</b>	Application # 10/573,804
	Confirmation # 9377
	Filing Date 03/28/06
	First Inventor AIACH
	Art Unit
	Examiner
	Docket # P08898US00/BAS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SIR :

**This IDS is submitted pursuant to 37 CFR. §1.97-1.98 and includes the following:**

- A listing of the references on PTO-1449.
- A copy of all **non-US** references which are listed on the PTO-1449 (US refs not required).
- A copy of a corresponding foreign **Search Report** which explains the relevance of the references noted therein.
- A separate explanation of relevance.

**Please note the following particulars concerning the filing of this IDS:**

- 1. This IDS is filed at whichever is the latest of:
  - within three months of the filing date of a NATIONAL APPLICATION other than a CPA, or
  - within three months of the date of entry into the NATIONAL STAGE as set forth in 37 CFR. §1.491 in an international application, or
  - before the mailing date of a first Office Action on the merits or after filing of an RCE (*but if a first Office Action is mailed but not yet received and the date on the face of the attached foreign communication makes it evident that this IDS is submitted within three months from the mailing of the search report, then applicant is entitled to have this IDS considered under 2.B. below and such boxes should be considered as having been checked*).
- 2. This IDS is filed after a first Office Action, but before a Final Action, Allowance, or any other action which closes prosecution, and:
  - A. Is accompanied by a payment in the amount of \$180.00 required by 37 CFR. §1.17(p).
  - or
  - B. I hereby state that each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.
  - C. I hereby state that no item of information in this IDS herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR. §1.56(c) more than 3 months prior to the filing of this IDS.
  - D. An appropriate Statement is attached.

3. This IDS is filed **after** a final action or allowance, but on/before payment of the issue fee, and:

A. is accompanied by a payment in the amount of \$180.00 required by 37 CFR. §1.17(p).

and

B. I hereby state that each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.

C. I hereby state that no item of information in this IDS herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR. §1.56(c) more than 3 months prior to the filing of this IDS.

D. An appropriate Statement is attached.


4. This IDS does not comply with 37 CFR 1.97-1.98, and is being filed **for placement in the file** pursuant to 37 CFR. §1.97(i). .

5. It will also be appreciated that:

- a. It is believed that this IDS complies fully with 37 CFR 1.56 and 1.97-98 and with MPEP § 609; but if for some reason it does not and will not be entered, the examiner is requested to telephone the undersigned so that any deficiency can be timely remedied.
- b. Some of the documents may have markings thereon, but no significance should be attached to those markings.
- c. These documents are not necessarily analogous art.
- d. Where an English language translation of an abstract is provided from a public source, applicant cannot vouch for the accuracy of that translation.

6. If no payment is enclosed and a fee is due in connection with this communication or if the payment enclosed is insufficient, the Director is authorized to charge any fee or additional fee due with this communication to Deposit Account No. 12-0555.

Respectfully submitted,

  
By: B. Aaron Schulman

Registration No.: 31,877

Date: May 21, 2007

STITES & HARBISON PLLC • 1199 North Fairfax St. • Suite 900 • Alexandria, VA 22314  
TEL: 703-739-4900 • FAX: 703-739-9577 • CUSTOMER No. 00881

Substitute for Form 1449A/PTO		Application #	10/573,804	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Confirmation #	9377	
		Filing Date	03/28/06	
		First Inventor	AIACH	
		Art Unit		
		Examiner		
Sheet 1 of 1		Docket #	P08898US00/BAS	
<b>U.S. PATENT DOCUMENTS</b>				
Exam. Initial*	Document No. Number - Kind	Publ. Date MM-DD-YYYY	Name Patentee or Applicant	Relevance Passages/Figs.
US-				
<b>FOREIGN PATENT DOCUMENTS</b>				
Exam. Initial*	Country-Number-Kind	Publ. Date MM-DD-YYYY	Name Patentee or Applicant	Relevance Passages/Figs.
<b>NON PATENT LITERATURE DOCUMENTS</b>				
Exam. Initial*	Include NAME of the author (in CAPS), Title of Article/Item, Date, Page(s), Volume-Issue No., Publisher, City and/or Country where published			Trans-lation
	HAYASHI et al, "Organization and chromosomal localization of the human endothelial protein C receptor gene." Oct. 1, 1999, pp. 367-373, vol. 238, no. 2			
	ESPANA et al, "A new polymorphism in the 3' UTR region of the endothelial protein C receptor associated with increased levels of circulating activated protein C and decreased risk of venous thrombosis", 2001, pg. 0C885, Thromb. Haemost.			
	MEDINA et al, "the 4678G/C polymorphism in the endothelial protein C receptor (EPCR) gene is associated with levels of soluble plasma EPCR", July 2003, p. P0026, vol. 1			
	DATABASE SNP "Online! NCBI: database accession no. RS2069945			
	DATABASE SNP "Online! NCBI: database accession no. RS867186			
	DATABASE SNP "Online! NCBI: database accession no. RS2069944			
	DATABASE SNP "Online! NCBI: database accession no. RS2069948			
	DATABASE SNP "Online! NCBI: database accession no. RS945960			
	DATABASE SNP "Online! NCBI: database accession no. RS2069950			
	DATABASE SNP "Online! NCBI: database accession no. RS9574			

Examiner Signature	Date Considered
--------------------	-----------------

\* Examiner: Initial if considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

PTO  
STAMPED RECEIPT

Application #	10/573,804
Confirmation #	9377
Filing Date	03/28/06
First Inventor	AIACH
Art Unit	
Examiner	
Docket #	P08898US00/BAS

PAPERS SUBMITTED

Transmittal Form  
 Amendment  
 with Attachments  
 Amendment/Response After Final  
 with Attachments  
 Petition for Extension of Time  
 Response to Missing Parts  
 Declaration  
 Translation of Application  
 Assignment  
 Priority Document  
 Fee of \$250 (CREDIT CARD - PTO-2038)  
 Copy of Notice

IDS: Including  
 List of References  
 Search Report  
10 Refs. Transmitted  
 Statement of Relevance  
 Issue Fee Transmittal  
 Publication Fee Transmittal  
 Letter to Draftsman

sheets of formal drawings  
(figs. )

Notice of Appeal  
 Appeal Brief

COPY

PTO Receipt Stamp →

